Limited Access to SGLT2 Inhibitors and GLP-1 Receptor Agonists Among Medicaid Enrollees
A recent study reveals that many Medicaid enrollees with type 2 diabetes face restricted access to vital cardioprotective medications, notably sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Published online on April 22 in the Annals of Internal Medicine, the research highlights significant disparities in medication availability across different Medicaid plans. The study assessed coverage by examining all 50 state Medicaid fee-for-service (FFS) plans and 273 managed care organization (MCO) plans for nonelderly adults as of March 2024.
Findings show that while 80% of FFS plans provide unrestricted access to SGLT2 inhibitors, only 60% offer unrestricted access to GLP-1 RAs. Overall, 82% of plans offered either medication without restrictions, but only 58% allowed unrestricted access to both. Coverage of dipeptidyl peptidase-4 inhibitors (DPP-4is), another class of diabetes medication, was higher, with 84% of plans providing unrestricted access. Among MCO plans, 67% had availability of SGLT2 inhibitors, and 48% offered GLP-1 RAs without restrictions, with considerable variability among states—ranging from 24% to 100% for SGLT2 inhibitors and 0% to 99% for GLP-1 RAs.
The study also notes that restricted medication access often results from specific MCO restrictions, and overall availability has improved from 2020 to 2024, especially within FFS plans. However, since 2022, GLP-1 RA coverage in MCO plans has plateaued below 60%. Notably, the medication tirzepatide remains nearly entirely restricted.
According to the authors, formulary plan coverage is a critical lever for addressing health inequities, especially for low-income Medicaid populations dealing with diabetes. Enhancing formulary access could significantly improve health outcomes and reduce disparities.
This research underscores the need for policy changes to improve access to these essential medications, which are proven to lower cardiovascular risks and aid in diabetes management.
Source: https://medicalxpress.com/news/2025-04-medicaid-enrollees-restricted-access-sglt2.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Variations in Healthcare Provider Stigma Toward Substance Use Disorders by Condition and Provider Type
A new nationwide study uncovers significant variations in healthcare providers' stigma toward substance use disorders and underscores barriers to effective treatment across diverse medical settings.
Recall of Ritz Peanut Butter Crackers Due to Labeling Error
A nationwide recall of Ritz Peanut Butter Crackers has been issued due to labeling errors that pose serious allergy risks. Consumers with peanut allergies should discard affected products immediately.
UK Reports 20% Reduction in Cancer Mortality Amid Rising Diagnoses
The UK has seen a 20% decrease in cancer mortality rates since the 1970s, accompanied by a near 50% rise in cancer diagnoses. Despite progress in survival and screening, systemic inequalities and lifestyle factors challenge the goal of equitable cancer care. Read more about the latest trends and ongoing efforts to address disparities in UK cancer outcomes.
Innovative Ultrasound Technique Enables Real-Time Brain Blood Flow Monitoring During Surgery
A new ultrasound method enables neurosurgeons to monitor brain blood flow live during surgery, reducing stroke risk and improving surgical safety with real-time blood perfusion imaging.